Company News
- Cyclo Therapeutics Signs Master Services Agreement with Worldwide Clinical Trials
Dec 27, 2019, 8:00 AM EST - Cyclo Therapeutics Receives Buy Recommendation and $1.25 Price Target from ThinkEquity
Dec 18, 2019, 7:00 AM EST - Cyclo Therapeutics, Inc. to Present Clinical Trial Data on Niemann-Pick type C Disease at the 16th Annual WORLDSymposium
Dec 16, 2019, 8:00 AM EST - Cyclo Therapeutics’ Chief Scientific Officer Appointed to President’s Council of Advisors on Science and Technology
Dec 10, 2019, 5:10 AM EST - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick Disease Type C
Nov 8, 2019, 8:00 AM EST - Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-Date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick Disease Type C
Oct 31, 2019, 8:00 AM EDT - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Alzheimer’s Disease Clinical Trial
Oct 30, 2019, 8:00 AM EDT - Cyclo Therapeutics Prepares for Alzheimer’s Development Program After Success with First Patient
Oct 28, 2019, 7:00 AM EDT - Cyclo Therapeutics, Inc. Chief Scientific Officer, Sharon H. Hrynkow, Ph.D., Appointed to President’s Council on Science and Technology
Oct 23, 2019, 8:00 AM EDT - Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Oct 22, 2019, 8:00 AM EDT
